The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.
Revolution Medicines Inc.’s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months, in addition ...
The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results